Cervarix
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 84 (Table of Contents)
Published: 7 Jun-2007
DOI: 10.3833/pdr.v2007.i84.338 ISSN: 1756-7874
Section: Deal Trackers
Fulltext:
Abstract
MedImmune and GlaxoSmithKline (GSK) are developing a recombinant, bivalent virus-like particle (VLP) HPV vaccine, Cervarix®, for the prevention of cervical cancer, which is formulated with a proprietary GSK adjuvant system, AS04...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS